When a cancer breakthrough comes with a price tag

Cancer treatment has changed in the past two decades. One of the biggest shifts has been immunotherapy, a treatment that helps the body’s own defences recognise and fight cancer. For some patients, it has brought longer lives and lasting control of diseases that once offered few options. But in Bangladesh, a powerful treatment raises a powerful question: who can afford it?

That question matters because medical progress does not arrive on equal terms. A few rounds of immunotherapy can cost as much as a family earns in an entire year. In Bangladesh, where patients still pay much of their healthcare bill themselves, a breakthrough can become a financial burden. The challenge, therefore, is not simply bringing advanced medicines into hospitals. It is making sure they reach people who are most likely to benefit without pushing families towards financial ruin.

Tap here to add The Daily Star as a trusted source

Bangladesh needs a national plan for immunotherapy built around fairness, evidence and affordability. The first step is choosing patients. Simple tests can help doctors identify whose cancer is more likely to respond, rather than offering an expensive treatment with little chance of success.

Clear national guidance is important. Doctors need a shared set of rules explaining which cancers should be treated with immunotherapy, when it should be used, how long treatment should continue and when it should stop. This could reduce unnecessary treatment while making care more consistent across hospitals.

Cost cannot be ignored. Government, hospitals, medicine companies and future health insurance schemes could work together to negotiate lower prices. Support programmes for patients, sensible tax measures and agreements where payment reflects treatment results could also ease the burden on families.

Bangladesh also needs to learn from its own patients. A national cancer record system could track how people respond to treatment, how long benefits last and what problems arise. Over time, this local evidence could help policymakers spend limited health funds more wisely.

Most importantly, patients must remain at the centre of every decision. Before starting such costly treatment, a team of cancer specialists should review each case. Patients and families should receive clear, plain-language information about likely benefits, possible harm, limits of treatment and the financial cost. Hope should never be sold without context.

A national oversight programme could bring these pieces together by guiding patient selection, testing, approval, follow-up and decisions about stopping treatment. Such a system could prevent waste while protecting both patients and the health system.

The principle is straightforward: the right medicine, for the right patient, at the right time, for the right length of time. Immunotherapy has already changed what is possible in cancer care. Bangladesh’s next challenge is to decide how that possibility can become practical.

A breakthrough should not remain a privilege for the few. With careful planning, fair selection, lower prices and transparent decisions, Bangladesh can move towards cancer care that embraces innovation without losing sight of affordability. The real measure of progress will not be whether the newest treatment is available, but whether it is used wisely, fairly and sustainably.

Dr Arman Reza Chowdhury is a Senior Consultant in Radiation Oncology at Evercare Hospital Dhaka. E-mail: rezadrarman@gmail.com